QCZ484 Clinical Trials (2026): 3 Studies for Hypertension & Hypertension (HTN)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 QCZ484 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Hypertension & Hypertension (HTN)) and 764 total planned enrollment. 1 QCZ484 clinical trial is actively recruiting at 6 U.S. sites across 5 states. Most recent activity: NCT07543120 (Nov 2031).
Where to Participate: All QCZ484 Trial Sites in the U.S. (6 sites across 5 states)
Every actively recruiting QCZ484trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | NICRs Research Center | Garden Grove92844 | NCT07543120 | Map |
| FL | Entrust Clinical Research | Miami33176 | NCT07543120 | Map |
| FL | Inpatient Research Clinical LLC | Miami Lakes33014 | NCT07543120 | Map |
| GA | Javara Research | Fayetteville30214 | NCT07543120 | Map |
| MD | Anderson Medical Research | Ft. Washington20744 | NCT07543120 | Map |
| NC | Monroe Biomedical Research | Monroe28112 | NCT07543120 | Map |
QCZ484 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 1 | 2 |
Recruiting QCZ484 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. | P2 | Hypertension (HTN) | 323 | May 2026 |
QCZ484 clinical trials by indication
Hypertension (HTN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07543120 | — | P2 | recruiting | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. |
Hypertension (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06857955 | — | P2 | active not recruiting | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients |
Mild Hypertension (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06905327 | — | P1 | completed | A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects |
All QCZ484 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. | P2 | recruiting | 323 | Novartis Pharmaceuticals | May 2026 | |
| NCT06857955 | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | P2 | active not recruiting | 385 | Novartis Pharmaceuticals | Mar 2025 | |
| NCT06905327 | A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects | P1 | completed | 56 | Novartis Pharmaceuticals | Mar 2023 |
QCZ484 clinical trials: frequently asked questions
- How many QCZ484 clinical trials are there?
- 3 QCZ484 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are QCZ484 clinical trials recruiting in 2026?
- Yes — 1 QCZ484 trial is actively recruiting in 2026, with 6 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is QCZ484 being studied for?
- QCZ484 is being studied for Hypertension, Hypertension (HTN), Mild Hypertension. The trials are grouped by indication on this page.
- What phase is QCZ484 in?
- QCZ484 clinical trials span 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors QCZ484 clinical trials?
- The lead sponsor across the most QCZ484 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming QCZ484as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: